- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 39/40 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum bacterial
Patent holdings for IPC class A61K 39/40
Total number of patents in this class: 886
10-year publication summary
|
55
|
81
|
67
|
51
|
44
|
47
|
39
|
34
|
22
|
8
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| MedImmune, LLC | 497 |
25 |
| Research Institute at Nationwide Children's Hospital | 625 |
16 |
| Xencor, Inc. | 408 |
16 |
| New York University | 1832 |
15 |
| The University of Chicago | 1483 |
13 |
| The Regents of the University of California | 20594 |
11 |
| Regeneron Pharmaceuticals, Inc. | 4638 |
11 |
| Humabs Biomed SA | 121 |
10 |
| Abbvie Inc. | 1839 |
9 |
| MacroGenics, Inc. | 230 |
9 |
| Merus N.V. | 194 |
9 |
| University of Rochester | 1324 |
9 |
| The Regents of the University of Michigan | 4928 |
8 |
| MedImmune Limited | 611 |
8 |
| Novartis AG | 10340 |
7 |
| Longhorn Vaccines and Diagnostics, LLC | 92 |
7 |
| National Research Council of Canada | 1538 |
7 |
| Xbiotech, Inc. | 65 |
7 |
| TLA Targeted Immunotherapies AB | 11 |
7 |
| Amgen Inc. | 4372 |
6 |
| Other owners | 676 |